Med Pediatr Oncol. 1978;4(4):337-42.

Remission induction in acute myelogenous leukemia using cytosine arabinoside synchronization: a Southwest Oncology Group Study.

Steuber CP, Humphrey GB, McMillan CW, Vietti TJ.

Abstract

The use of cytosine arabinoside (Ara-C) infused at kinetically suggested intervals is reported in 40 pediatric patients with acute myelogenous leukemia (AML) and its subtypes. Response was observed in 17 of the 34 evaluable patients. However, the severe, often fatal effects of the regimen prevent its recommendation as a standard induction regimen in AML in children.

PMID:: 281596; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, U.S. Gov't, P.H.S.

MeSH Terms

Substances

Cytarabine

LinkOut - more resources

Supplemental Content

Save items

Related citations in PubMed

Manipulation of the mitotic cycle in the treatment of acute myelogenous leukaemia. [Br J Haematol. 1976]
Manipulation of the mitotic cycle in the treatment of acute myelogenous leukaemia.
Lampkin BC, McWilliams NB, Mauer AM, Flessa HC, Hake DA, Fisher V. Br J Haematol. 1976 Jan; 32(1):29-40.
Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group. [Clin Cancer Res. 1998]
Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK. Clin Cancer Res. 1998 Jan; 4(1):45-52.
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group. [Ann Hematol. 1996]
Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: a phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group.
De Witte T, Suciu S, Selleslag D, Labar B, Roozendaal K, Zittoun R, Ribeiro M, Kurstjens R, Hayat M, Dardenne M, et al. Ann Hematol. 1996 Mar; 72(3):119-24.
Review [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia]. [Rev Invest Clin. 1989]
Review [High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].
Lobato-Mendizábal E, Ruiz-Argüelles GJ, Marín-López A. Rev Invest Clin. 1989 Apr-Jun; 41(2):139-45.
Review Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. [Leukemia. 1987]
Review Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
Bolwell BJ, Cassileth PA, Gale RP. Leukemia. 1987 Aug; 1(8):575-9.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound
PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance
PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Remission induction in acute myelogenous leukemia using cytosine arabinoside syn...
Remission induction in acute myelogenous leukemia using cytosine arabinoside synchronization: a Southwest Oncology Group Study.
Med Pediatr Oncol. 1978 ;4(4):337-42.

PubMed
Hyperthermic perfusion with chemotherapy for melanoma of the extremities.
Hyperthermic perfusion with chemotherapy for melanoma of the extremities.
World J Surg. 1989 Sep-Oct ;13(5):598-602.

PubMed
Analysis of human cancer DNA for DNA sequences of human adenovirus type 4.
Analysis of human cancer DNA for DNA sequences of human adenovirus type 4.
J Natl Cancer Inst. 1979 Jan ;62(1):23-6.

PubMed
Severe acquired deficiency of vitamin K-dependent factors and resistance to mult...
Severe acquired deficiency of vitamin K-dependent factors and resistance to multiple vitamin K injections.
Thromb Haemost. 1989 Sep 29 ;62(2):816.

PubMed
Twins, smoking and mortality: a 12-year prospective study of smoking-discordant ...
Twins, smoking and mortality: a 12-year prospective study of smoking-discordant twin pairs.
Soc Sci Med. 1989 ;29(9):1083-9.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Remission induction in acute myelogenous leukemia using cytosine arabinoside synchronization: a Southwest Oncology Group Study.

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information